Helix BioPharmaHBPCF 28 3-Year ROIIC % is 3.96 as of Jul. 2025, which is 80% below its 10-year median of 19.90. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,323 Biotechnology companies, Helix BioPharma ranks better than 56.76% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Helix BioPharma's 3-Year ROIIC % for the quarter that ended in Jul. 2025 was 3.96%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Helix BioPharma's 3-Year ROIIC % or its related term are showing as below:
HBPCF's 3-Year ROIIC % is ranked better than 56.76% of 1323
companies
in the Biotechnology industry
Industry Median: -4.82
vs HBPCF: 3.96
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Helix BioPharma 3-Year ROIIC % Related Terms
Helix BioPharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBPCF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Helix BioPharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's 3-Year ROIIC % falls into.
Helix BioPharma's 3-Year ROIIC % for the quarter that ended in Jul. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.942 (Jul. 2025) - -4.669 (Jul. 2022) )
/
( 13.679 (Jul. 2025) - 1.936 (Jul. 2022) )
=
0.727
/
11.743
=
6.19%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Helix BioPharma (HBPCF) has a 3-Year ROIIC % of 3.96 as of Jul. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Helix BioPharma and its competitors. This is 80% below median its historical median of 19.90. According to the industry distribution chart, Helix BioPharma ranks #572 out of 1323 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Helix BioPharma's 3-Year ROIIC % too high?
Helix BioPharma's current 3-Year ROIIC % of 3.96 is 80% below median its 10-year median of 19.90. Based on the distribution chart, Helix BioPharma ranks #572 out of 1323 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #572 out of 1323 companies for 3-Year ROIIC %. This puts Helix BioPharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current 3-Year ROIIC % is 3.96, which is 80% below median its own 10-year median of 19.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current 3-Year ROIIC % of 3.96. The current 3-Year ROIIC % is 3.96, which is 80% below median its 10-year median of 19.90. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current 3-Year ROIIC % is 3.96 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
